Author:
Zecchini Tracey Ann,Wright Paul Andrew,Smith Rodney John
Publisher
Springer Science and Business Media LLC
Subject
Biomedical Engineering,Applied Microbiology and Biotechnology,Bioengineering,Biotechnology
Reference10 articles.
1. Corey L. (1993) Herpes simplex virus infections during sthe decade since the licensure of acyclovin.J. Med. Virol. Suppl. 1: 7–12.
2. McLean, C. S., M. Erturk, R. Jennings, D. Ni Challa-nain, A. C. Minson, M. E. G. Boursnell, and S. C. Inglis (1994) Protective vaccination against primary and recurrent disease caused by herpes simplex virus type 2 using a genetically disabled herpes simplex virus type 1.J. Infec. Dis. 170: 1100–1109.
3. Boursnell M. E. G., C. Entwistle, D. Blakely, C. Roberts, I. Duncan, S. E. Chisholm, G. M. Martin, R. Jennings, D. Ni Challanain, I. Sobek, and C. S. McLean (1997) A genetically inactivated Herpes Simplex Virus Type 2 (HSV) vaccine provides effective protection against primary and recurrent HSV disease.J. Infec. Dis. 175: 16–25.
4. Zecchini T. A. and R. J. Smith (1997) Production of high titre DISC-HSV-2 from a microcarrier culture. pp. 569–571. In: O. Merton, P. Perrin, and Griffiths B. (ed).New Developments and New Applications in Animal Cell Technology Kluwer Acedemic Publishers, Dordrecht, Netherlands.
5. Zecchini T. A. and R. J. Smith (1999) Production of high titre disabled infectious single cycle (DISC) HSV from a microcarrier culture in.Cytotechnology 30: 203–210.